Cite
Characterization of stability, safety and immunogenicity of the mRNA lipid nanoparticle vaccine Iribovax® against COVID-19 in nonhuman primates.
MLA
Zamani, Parvin, et al. “Characterization of Stability, Safety and Immunogenicity of the MRNA Lipid Nanoparticle Vaccine Iribovax® against COVID-19 in Nonhuman Primates.” Journal of Controlled Release : Official Journal of the Controlled Release Society, vol. 360, Aug. 2023, pp. 316–34. EBSCOhost, https://doi.org/10.1016/j.jconrel.2023.06.025.
APA
Zamani, P., Mashreghi, M., Rezazade Bazaz, M., Zargari, S., Alizadeh, F., Dorrigiv, M., Abdoli, A., Aminianfar, H., Hatamipour, M., Zarqi, J., Behboodifar, S., Samsami, Y., Khorshid Sokhangouy, S., Sefidbakht, Y., Uskoković, V., Rezayat, S. M., Jaafari, M. R., & Mozaffari-Jovin, S. (2023). Characterization of stability, safety and immunogenicity of the mRNA lipid nanoparticle vaccine Iribovax® against COVID-19 in nonhuman primates. Journal of Controlled Release : Official Journal of the Controlled Release Society, 360, 316–334. https://doi.org/10.1016/j.jconrel.2023.06.025
Chicago
Zamani, Parvin, Mohammad Mashreghi, Mahere Rezazade Bazaz, Selma Zargari, Farzaneh Alizadeh, Mahyar Dorrigiv, Asghar Abdoli, et al. 2023. “Characterization of Stability, Safety and Immunogenicity of the MRNA Lipid Nanoparticle Vaccine Iribovax® against COVID-19 in Nonhuman Primates.” Journal of Controlled Release : Official Journal of the Controlled Release Society 360 (August): 316–34. doi:10.1016/j.jconrel.2023.06.025.